Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS), By Type(IgG, IgM, IgA, IgE), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy, and Others), By Region - Industry Forecast 2024-2031

In January 2024, the US Food & Drug Administration (FDA) has approved Takeda’s HYQVIA (immune globulin infusion (human) 10% solution) to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). According to a company press release, HYQVIA is the only FDA-approved combination of IG and hyaluronidase, making it a facilitated subcutaneous IG (SCIG) infusion.

In July 2023, GC Biopharma has announced that it has signed a deal with Blau Farmaceutica, a Brazilian partner, to supply its immunoglobulin blood product, Immune Globulin Intravenous (IVIG-SN5%), to Brazil until 2028. The GC Biopharma blood products are at an estimated cost of $90.48 million. Brazil is the largest market for blood products in South America, with an estimated market size of $270 million for immunoglobulins as of 2022.

In June 2023, Drug Administration of Vietnam under the Ministry of Health (MoH) had imported 6,000 bottles of Plasma-derived Intravenous Immunoglobulin (IVIG) to Vietnam to supply local hospitals for treatment of hand, foot and mouth disease (HFMD). According to details given by the MoH, the quantity of drugs met the urgent needs of hospitals. However, due to sharp increases in infection numbers, the MoH requested that importers move to ensure IVIG drug supply in a bid to meet the increasing demand of the hospitals.